Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CERCA
MCID: CRV035
MIFTS: 73

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cervical Cancer

About this section

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 57 12 74 73 36 54 42 3 15 62 71
Neoplasm of Uterine Cervix 12 29 6
Cervical Cancer, Somatic 57 13 6
Uterine Cervical Neoplasm 12 71
Cervix Cancer 12 73
Uterine Cervical Neoplasms 44
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 39
Malignant Tumor of Cervix 71
Uterine Cervical Cancer 73
Cervix Uteri Cancer 12
Neoplasms Cervical 54
Cervical Neoplasm 12
Cervix Carcinoma 71
Cervical Cancers 15
Cerca 73

Characteristics:

HPO:

31
cervical cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4362
OMIM® 57 603956
KEGG 36 H00030
ICD9CM 34 180
MeSH 44 D002583
NCIt 50 C2940 C9311
SNOMED-CT 67 123841004 254885005
ICD10 32 C53
SNOMED-CT via HPO 68 108369006 124975008 363346000
UMLS 71 C0007847 C0007873 C0302592 more
Sources

Summaries for Cervical Cancer

About this section
MedlinePlus : 42 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as neoplasm of uterine cervix, is related to cervix carcinoma and adenocarcinoma, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include cervix, breast and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix connects the vagina (birth canal) to the upper part of the uterus. The uterus (or womb) is where a baby grows when a woman is pregnant. All women are at risk for cervical cancer. It occurs most often in women over age 30. Human papillomavirus (HPV) is the main cause of cervical cancer. HPV is a common virus that is passed from one person to another during sex. At least half of sexually active people will have HPV at some point in their lives, but few women will get cervical cancer. Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

KEGG : 36 Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types, particularly types 16, 18, 33 and 42. Experimental studies show that the E6 and E7 genes of these high risk HPVs are oncogenes that deregulate key cell cycle controls. The E6 and E7 oncoproteins bind respectively to the p53 and Retinoblastoma (Rb) tumor suppressor proteins, which are involved in the regulation of growth control. The abnormalities in other cellular genes found in cervical cancer, including mutations in ras family of genes, and amplification in EGFR and ERBB2, may also play an important role in carcinogenesis and the aggressiveness of cervical tumors, although to date the role of most of these genetic abnormalities does not appear to be as important as the role of HPV.

UniProtKB/Swiss-Prot : 73 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 62 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer. The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 74 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

More information from OMIM: 603956
Sources

Related Diseases for Cervical Cancer

About this section

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 32.9 TP53 STAT3 MIR214 FGFR3
2 adenocarcinoma 32.3 TP53 STAT3 MALAT1 H19 FGFR3 CCND1
3 cervical squamous cell carcinoma 32.2 TP53 STAT3 CCND1
4 squamous cell carcinoma 32.1 UCA1 TUG1 TP53 STAT3 NEAT1 MALAT1
5 b-cell lymphoma 31.9 TUG1 TP53 STAT3 PVT1 MIR21 MALAT1
6 endometrial cancer 31.8 UCA1 TUG1 TP53 STAT3 NEAT1 HOTAIR
7 retinoblastoma 31.6 TP53 MALAT1 HOTAIR CCND1 CCAT1
8 melanoma 31.3 UCA1 TP53 STAT3 PVT1 MALAT1 HOTAIR
9 sarcoma 31.3 TP53 STAT3 HOTAIR FGFR3 CCND1
10 lung cancer susceptibility 3 31.3 TUG1 TP53 STAT3 MIR21 MALAT1 HOTAIR
11 bladder cancer 31.2 UCA1 TUG1 TP53 PVT1 MIR214 MIR21
12 breast cancer 31.2 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
13 leukemia 31.2 TP53 STAT3 NEAT1 HOTAIR GAS5 CDKN2B-AS1
14 ovarian cancer 31.2 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
15 oral cancer 31.1 TP53 MIR21 CCND1
16 endometrial adenocarcinoma 31.1 TP53 MALAT1 CCND1
17 esophageal cancer 31.0 UCA1 TP53 STAT3 PVT1 MIR21 MALAT1
18 glioblastoma 31.0 TUG1 TP53 STAT3 MIR21 MALAT1 HOTAIR
19 leukemia, acute myeloid 31.0 UCA1 TUG1 TP53 STAT3 MIR21 MALAT1
20 leukemia, chronic lymphocytic 31.0 TP53 STAT3 NEAT1 MIR214 MIR21 CRNDE
21 osteogenic sarcoma 31.0 UCA1 TUG1 TP53 PVT1 NEAT1 MALAT1
22 retinitis pigmentosa 11 31.0 UCA1 TUG1 TP53 PVT1 NEAT1 HOTAIR
23 skin melanoma 30.9 TP53 STAT3 MIR214 CCND1
24 nasopharyngeal carcinoma 30.9 TP53 STAT3 PVT1 NEAT1 MIR21 MALAT1
25 acute promyelocytic leukemia 30.9 TP53 STAT3 PVT1 NEAT1 CCND1
26 lymphangioma 30.9 TP53 STAT3 CCND1
27 ovarian epithelial cancer 30.8 MALAT1 HOTAIR H19 CCAT1
28 lung cancer 30.8 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
29 colorectal adenoma 30.8 TP53 MIR21 CCND1
30 diffuse large b-cell lymphoma 30.8 TP53 STAT3 MIR21 HOTAIR CCND1
31 rhabdomyosarcoma 30.8 TP53 STAT3 H19 FGFR3 CCND1
32 laryngeal squamous cell carcinoma 30.8 TP53 NEAT1 MIR21 MALAT1 HOTAIR H19
33 thyroid carcinoma 30.8 UCA1 PVT1 NEAT1 MALAT1 HOTAIR H19
34 tongue squamous cell carcinoma 30.8 UCA1 TP53 STAT3 MIR21 MALAT1 CCND1
35 small cell cancer of the lung 30.8 TUG1 TP53 MIR21 MALAT1 HOTAIR
36 gastric cancer 30.8 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
37 kidney cancer 30.7 TP53 PVT1 MIR214 MIR21 MALAT1 HOTAIR
38 squamous cell carcinoma, head and neck 30.7 TP53 STAT3 MIR214 MIR21 HOTAIR H19
39 burkitt lymphoma 30.7 TP53 STAT3 PVT1 NEAT1 MIR21
40 thyroid cancer, nonmedullary, 1 30.6 PVT1 NEAT1 MALAT1 HOTAIR H19
41 hepatocellular carcinoma 30.6 UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
42 gastrointestinal system cancer 30.6 MIR214 MIR21 MALAT1 HOTAIR H19
43 peripheral t-cell lymphoma 30.6 TP53 STAT3 FGFR3 CCND1
44 mantle cell lymphoma 30.6 TP53 STAT3 MALAT1 GAS5 CCND1
45 bladder urothelial carcinoma 30.6 TUG1 TP53 PVT1 MALAT1 HOTAIR GAS5
46 colorectal cancer 30.5 UCA1 TUSC8 TUG1 TP53 STAT3 PVT1
47 lung squamous cell carcinoma 30.5 TUG1 TP53 PVT1 FGFR3 CCND1 CCAT1
48 oral squamous cell carcinoma 30.4 UCA1 TUG1 TP53 NEAT1 MIR21 MALAT1
49 myeloma, multiple 30.4 UCA1 TUG1 TP53 STAT3 PVT1 MIR21
50 bone sarcoma 30.4 TP53 MIR214 MIR21

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer
Sources

Symptoms & Phenotypes for Cervical Cancer

About this section

Human phenotypes related to Cervical Cancer:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm 31 HP:0002664
2 abnormality of the cervical spine 31 HP:0003319

Clinical features from OMIM®:

603956 (Updated 05-Mar-2021)

UMLS symptoms related to Cervical Cancer:


pelvic pain
Sources

Drugs & Therapeutics for Cervical Cancer

About this section

PubMed Health treatment related to Cervical Cancer: 62

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization ) might be enough. If the tumor has already spread to the surrounding tissue , doctors usually recommend having surgery to remove the entire womb (a hysterectomy ). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy .

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
3
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Meperidine Approved Phase 4 57-42-1 4058
6
Bethanechol Approved Phase 4 674-38-4 2370
7
Ferrous fumarate Approved Phase 4 141-01-5
8
Iron Approved Phase 4 7439-89-6 23925 29936
9
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
10 Epoetin alfa Phase 4 113427-24-0
11 Cholinergic Agents Phase 4
12 Dopamine Agents Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Dopamine Uptake Inhibitors Phase 4
15 Antidepressive Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Narcotics Phase 4
18 Anesthetics, Intravenous Phase 4
19 Anesthetics, General Phase 4
20 Monophosphoryl lipid A Phase 4
21 Calamus Phase 4
22 Muscarinic Agonists Phase 4
23 Nutrients Phase 4
24 Micronutrients Phase 4
25 Trace Elements Phase 4
26 Vitamins Phase 4
27 Immunologic Factors Phase 4
28 Vaccines Phase 4
29 Fluorodeoxyglucose F18 Phase 4
30
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
31
Hydralazine Approved Phase 3 86-54-4 3637
32
Fluspirilene Approved, Investigational Phase 3 1841-19-6 3396
33
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
34
Vinblastine Approved Phase 3 865-21-4 13342 241903
35
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
36
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
37
Dalteparin Approved Phase 3 9005-49-6
38
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
39
Ondansetron Approved Phase 3 99614-02-5 4595
40
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
41
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
42
Aluminum sulfate Approved Phase 3 10043-01-3
43
Calcium polycarbophil Approved Phase 3 126040-58-2
44
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
45
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
46
Durvalumab Approved, Investigational Phase 3 1428935-60-7
47
Bevacizumab Approved, Investigational Phase 3 216974-75-3
48
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
49
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
50
Cemiplimab Approved, Investigational Phase 3 1801342-60-8

Interventional clinical trials:

(show top 50) (show all 1225)
# Name Status NCT ID Phase Drugs
1 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
2 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
3 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
4 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
6 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
7 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
8 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
9 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Completed NCT01101750 Phase 4
10 Work Package 4: HPV Vaccination of Women in Screening Ages Completed NCT02837926 Phase 4
11 Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany Completed NCT02296255 Phase 4
12 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
13 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
14 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Completed NCT03105856 Phase 4
15 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
16 Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial Completed NCT02684942 Phase 4 Meperidine;Fentanyl
17 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Completed NCT02910596 Phase 4 bethanechol chloride
18 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Recruiting NCT03349463 Phase 4 Fluciclovine F18
19 Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening Active, not recruiting NCT01895517 Phase 4
20 Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
21 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
22 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
23 A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
24 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Terminated NCT03423082 Phase 4 18F fluciclovine
25 The Influence of the Pre-Therapeutic Increase in the Hemoglobin Level in the Blood Through Erythropoietin to the Therapy Results of the Primary Radiation Therapy for Carcinoma of the Cervix Unknown status NCT00348738 Phase 3 Erythropoietin
26 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
27 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
28 Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis Unknown status NCT00846508 Phase 3 Cisplatin
29 Improvement of Locally Advanced Cervical Cancer Radiotherapy Efficacy by Use of Volumetric Arc Therapy, Individualized Polyradiosensitization and Interstitial Brachytherapy Unknown status NCT02957266 Phase 3 Cisplatin;Gemcitabine
30 Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial Unknown status NCT03308591 Phase 3 NACT;Adjuvant chemotherapy
31 Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
32 Randomised Phase III Clinical Trial on Concurent Chemoradiation vs. Neoadjuvant Chemoradiation and Surgery vs. Neoadjuvant Chemotherapy and Surgery in Early Stage Bulky Cervical Cancers (FIGO Stages IB2, IIA2 and IIB) Unknown status NCT01917695 Phase 3 Chemotherapy
33 A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
34 A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer Unknown status NCT01405235 Phase 3 Paclitaxel;Cisplatin/Paclitaxel
35 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3
36 Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer Unknown status NCT02703961 Phase 3 concurrent chemotherapy with cisplatin;concurrent chemotherapy with docetaxel;adjuvant chemotherapy with cisplatin and docetaxel
37 Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin（DDP） weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
38 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
39 Phase III Clinical Trial: "Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer Unknown status NCT02446652 Phase 3 Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
40 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer. Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo
41 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
42 Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
43 Individualized Precise Radiotherapy With the Guidance of Radiosensitivity: A Study on the Clinical Management Model of Locally Advanced Cervical Cancer Unknown status NCT03163979 Phase 2, Phase 3
44 A Phase III Randomised Trial Investigating the Benefits of the Addition of Modulated Electro-hyperthermia to Chemo-radiation for Cervical Cancer in HIV Positive and Negative Women in South Africa Unknown status NCT03332069 Phase 3 Cisplatin
45 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
46 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Unknown status NCT02595554 Phase 3 Paclitaxel;Cisplatin
47 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Unknown status NCT00943722 Phase 3
48 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
49 The Study of Folate Receptor-Mediated Staining Solution (FRDâ„¢) In Cervical Unknown status NCT03366493 Phase 3
50 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

About this section

Genetic tests related to Cervical Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Uterine Cervix 29
Sources

Anatomical Context for Cervical Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

19
Cervix

MalaCards organs/tissues related to Cervical Cancer:

40
Cervix, Breast, Lymph Node, Uterus, Bone, Endothelial, T Cells
Sources

Publications for Cervical Cancer

About this section

Articles related to Cervical Cancer:

(show top 50) (show all 30317)
# Title Authors PMID Year
1
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 61 54 57 6
1349102 1992
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 6 57
10471491 1999
3
Somatic LKB1 mutations promote cervical cancer progression. 61 57 54
19340305 2009
4
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. 57 61
23266353 2013
5
Efficacy of the combination of endostar with chemotherapy on stage IVb and recurrent metastatic cervical cancer. 61 42
33472996 2020
6
Deciphering the Role of Human Gastrointestinal Microbiota in the Pathogenesis of Vaginal Infection and Cervical Cancer. 42 61
33389908 2020
7
Landscape of genomic alterations in cervical carcinomas. 57
24390348 2014
8
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. 61 47
19859982 2009
9
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. 61 47
19682430 2009
10
Patterns of known and novel small RNAs in human cervical cancer. 47 61
17616659 2007
11
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 57
17360030 2007
12
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
13
Genetic link to cervical tumours. 57
10403244 1999
14
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 6
8589699 1995
15
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 57
8041728 1994
16
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 6
1849234 1991
17
A genetic model for colorectal tumorigenesis. 57
2188735 1990
18
The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma. 42
33429737 2021
19
HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. 54 61
20206160 2010
20
DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. 54 61
20442293 2010
21
ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. 61 54
20372863 2010
22
Analysis of expression and structure of the TSG101 gene in cervical cancer cells. 61 54
20372822 2010
23
Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). 61 54
19786613 2010
24
Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. 54 61
20167600 2010
25
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 61 54
20429915 2010
26
TP53, MDM2, NQO1, and susceptibility to cervical cancer. 61 54
20200430 2010
27
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). 54 61
19816757 2010
28
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. 54 61
19913895 2010
29
Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. 61 54
20213048 2010
30
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. 54 61
20193846 2010
31
Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. 54 61
20015862 2010
32
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. 54 61
19700237 2010
33
Anti-angiogenesis agents in metastatic or recurrent cervical cancer. 54 61
19861227 2010
34
[Exploring the issue of cervical cancer prevention and control in women living with HIV/AIDS]. 54 61
20127625 2010
35
Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women. 61 54
19730990 2010
36
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. 54 61
19949677 2009
37
[Mechanism of anti-tumor effect of HIF-1alpha silencing on cervical cancer in nude mice]. 61 54
20137345 2009
38
Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. 54 61
19755648 2009
39
Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. 54 61
19878546 2009
40
Tristetraprolin: a weapon against HPV-induced cervical cancer? 54 61
20157555 2009
41
Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. 54 61
19574249 2009
42
Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. 54 61
19680685 2009
43
The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. 61 54
20157568 2009
44
Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. 54 61
19672258 2009
45
Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia. 61 54
19723043 2009
46
The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. 61 54
19820361 2009
47
Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells. 54 61
19723056 2009
48
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. 54 61
19625214 2009
49
The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. 61 54
19578736 2009
50
[Effects of tumor metastasis suppressor gene nm23-H1 on invasion and proliferation of cervical cancer cell lines]. 61 54
19624895 2009
Sources

Variations for Cervical Cancer

About this section

ClinVar genetic disease variations for Cervical Cancer:

6 (show top 50) (show all 145)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.747G>T SNV Pathogenic 12352 rs28934571 17:7577534-7577534 17:7674216-7674216
2 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
3 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
4 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
5 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
6 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
7 FGFR3 NM_000142.5(FGFR3):c.1138G>A SNV Pathogenic 16327 rs28931614 4:1806119-1806119 4:1804392-1804392
8 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
9 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
10 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu) SNV Likely pathogenic 376386 rs1057519884 16:3788617-3788617 16:3738616-3738616
11 PIK3CA NM_006218.4(PIK3CA):c.1031T>G (p.Val344Gly) SNV Likely pathogenic 376497 rs1057519941 3:178921549-178921549 3:179203761-179203761
12 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely pathogenic 376484 rs1057519935 3:178916945-178916945 3:179199157-179199157
13 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg) SNV Likely pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
14 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely pathogenic 376478 rs1057519929 3:178916854-178916854 3:179199066-179199066
15 HRAS NM_005343.4(HRAS):c.436G>C (p.Ala146Pro) SNV Likely pathogenic 376442 rs104894231 11:533467-533467 11:533467-533467
16 NFE2L2 NM_006164.5(NFE2L2):c.85G>T (p.Asp29Tyr) SNV Likely pathogenic 376462 rs1057519920 2:178098960-178098960 2:177234232-177234232
17 TP53 NM_000546.5(TP53):c.581T>G (p.Leu194Arg) SNV Likely pathogenic 376633 rs1057519998 17:7578268-7578268 17:7674950-7674950
18 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His) SNV Likely pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
19 TP53 NM_000546.5(TP53):c.394A>C (p.Lys132Gln) SNV Likely pathogenic 376628 rs747342068 17:7578536-7578536 17:7675218-7675218
20 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
21 CTNNB1 NM_001904.4(CTNNB1):c.109T>G (p.Ser37Ala) SNV Likely pathogenic 376235 rs121913228 3:41266112-41266112 3:41224621-41224621
22 PIK3CA NM_006218.4(PIK3CA):c.112C>T (p.Arg38Cys) SNV Likely pathogenic 376493 rs749415085 3:178916725-178916725 3:179198937-179198937
23 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg) SNV Likely pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
24 CTNNB1 NM_001904.4(CTNNB1):c.94G>T (p.Asp32Tyr) SNV Likely pathogenic 17581 rs28931588 3:41266097-41266097 3:41224606-41224606
25 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely pathogenic 376423 rs149680468 4:153247289-153247289 4:152326137-152326137
26 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Likely pathogenic 13654 rs121913286 3:178936094-178936094 3:179218306-179218306
27 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 3:178936083-178936083 3:179218295-179218295
28 PIK3CA NM_006218.4(PIK3CA):c.112C>A (p.Arg38Ser) SNV Likely pathogenic 376494 rs749415085 3:178916725-178916725 3:179198937-179198937
29 TP53 NM_000546.5(TP53):c.580C>T (p.Leu194Phe) SNV Likely pathogenic 127817 rs587780071 17:7578269-7578269 17:7674951-7674951
30 NFE2L2 NM_006164.5(NFE2L2):c.236A>T (p.Glu79Val) SNV Likely pathogenic 376467 rs1057519923 2:178098809-178098809 2:177234081-177234081
31 TP53 NM_000546.5(TP53):c.712T>G (p.Cys238Gly) SNV Likely pathogenic 376577 rs1057519981 17:7577569-7577569 17:7674251-7674251
32 CTNNB1 NM_001904.4(CTNNB1):c.94G>C (p.Asp32His) SNV Likely pathogenic 376054 rs28931588 3:41266097-41266097 3:41224606-41224606
33 TP53 NM_001126115.1(TP53):c.-2A>C SNV Likely pathogenic 376627 rs1057519996 17:7578535-7578535 17:7675217-7675217
34 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Likely pathogenic 12368 rs121912660 17:7577099-7577099 17:7673781-7673781
35 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu) SNV Likely pathogenic 376424 rs1057519896 4:153247288-153247288 4:152326136-152326136
36 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely pathogenic 376475 rs1057519927 3:178936083-178936083 3:179218295-179218295
37 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 16:3788618-3788618 16:3738617-3738617
38 SMAD4 NM_005359.6(SMAD4):c.1082G>C (p.Arg361Pro) SNV Likely pathogenic 376541 rs377767347 18:48591919-48591919 18:51065549-51065549
39 TP53 NM_000546.5(TP53):c.581T>C (p.Leu194Pro) SNV Likely pathogenic 376635 rs1057519998 17:7578268-7578268 17:7674950-7674950
40 PIK3CA NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His) SNV Likely pathogenic 376491 rs1057519940 3:178936096-178936096 3:179218308-179218308
41 ERBB3 NM_001005915.1(ERBB3):c.310G>A (p.Val104Met) SNV Likely pathogenic 376410 rs1057519893 12:56478854-56478854 12:56085070-56085070
42 MAPK1 NM_138957.3(MAPK1):c.964G>A (p.Glu322Lys) SNV Likely pathogenic 376450 rs1057519911 22:22127164-22127164 22:21772875-21772875
43 PIK3CA NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala) SNV Likely pathogenic 376499 rs1057519941 3:178921549-178921549 3:179203761-179203761
44 CREBBP NM_004380.3(CREBBP):c.4337G>A (p.Arg1446His) SNV Likely pathogenic 376387 rs1057519884 16:3788617-3788617 16:3738616-3738616
45 SMAD4 NM_005359.6(SMAD4):c.1081C>G (p.Arg361Gly) SNV Likely pathogenic 24830 rs80338963 18:48591918-48591918 18:51065548-51065548
46 PIK3CA NM_006218.4(PIK3CA):c.113G>A (p.Arg38His) SNV Likely pathogenic 376492 rs772110575 3:178916726-178916726 3:179198938-179198938
47 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
48 NFE2L2 NM_006164.5(NFE2L2):c.86A>G (p.Asp29Gly) SNV Likely pathogenic 376464 rs1057519921 2:178098959-178098959 2:177234231-177234231
49 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely pathogenic 376414 rs867384286 4:153249385-153249385 4:152328233-152328233
50 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely pathogenic 376415 rs1057519895 4:153249384-153249384 4:152328232-152328232

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss NTM Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss FGF3 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POU3F2 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB1 Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion STK11 Cervical Cancer
35 124598 19 1156797 1179434 Deletion STK11 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification MRGBP Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain ANIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer
Sources

Expression for Cervical Cancer

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Cancer patients vs. healthy controls: 35 (show top 50) (show all 70)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 KRT1 keratin 1 Uterus - 5.47 0.000
2 KRTDAP keratinocyte differentiation associated protein Uterus - 4.96 0.000
3 CTHRC1 collagen triple helix repeat containing 1 Uterus + 4.65 0.000
4 TMPRSS11B transmembrane serine protease 11B Uterus - 4.58 0.000
5 CDKN2A cyclin dependent kinase inhibitor 2A Uterus + 4.45 0.000
6 CMPK2 cytidine/uridine monophosphate kinase 2 Uterus + 4.32 0.000
7 CRNN cornulin Uterus - 4.25 0.000
8 MAL mal, T cell differentiation protein Uterus - 4.21 0.000
9 DSG1 desmoglein 1 Uterus - 4.17 0.000
10 ECT2 epithelial cell transforming 2 Uterus + 4.10 0.000
11 SYCP2 synaptonemal complex protein 2 Uterus + 3.95 0.000
12 HS6ST2 heparan sulfate 6-O-sulfotransferase 2 Uterus + 3.94 0.000
13 KIF14 kinesin family member 14 Uterus + 3.88 0.000
14 IFI44 interferon induced protein 44 Uterus + 3.88 0.000
15 MMP1 matrix metallopeptidase 1 Uterus + 3.83 0.001
16 GREB1 growth regulating estrogen receptor binding 1 Uterus - 3.78 0.000
17 KRT17 keratin 17 Uterus + 3.71 0.000
18 SPINK7 serine peptidase inhibitor Kazal type 7 Uterus - 3.70 0.000
19 NUF2 NUF2 component of NDC80 kinetochore complex Uterus + 3.70 0.000
20 NCEH1 neutral cholesterol ester hydrolase 1 Uterus + 3.64 0.000
21 PLSCR1 phospholipid scramblase 1 Uterus + 3.63 0.000
22 E2F7 E2F transcription factor 7 Uterus + 3.62 0.000
23 SLF1 SMC5-SMC6 complex localization factor 1 Uterus + 3.61 0.000
24 INHBA inhibin subunit beta A Uterus + 3.59 0.001
25 DAPL1 death associated protein like 1 Uterus - 3.57 0.000
26 KRT4 keratin 4 Uterus - 3.53 0.000
27 SMC4 structural maintenance of chromosomes 4 Uterus + 3.50 0.000
28 CEP55 centrosomal protein 55 Uterus + 3.49 0.000
29 LOX lysyl oxidase Uterus + 3.48 0.000
30 ANLN anillin actin binding protein Uterus + 3.48 0.000
31 ITGB1 integrin subunit beta 1 Uterus + 3.46 0.000
32 CRISP3 cysteine rich secretory protein 3 Uterus - 3.46 0.001
33 HELLS helicase, lymphoid specific Uterus + 3.44 0.000
34 KRT19 keratin 19 Uterus + 3.44 0.002
35 SPP1 secreted phosphoprotein 1 Uterus + 3.43 0.000
36 CNFN cornifelin Uterus - 3.42 0.000
37 EPCAM epithelial cell adhesion molecule Uterus + 3.39 0.000
38 NDC80 NDC80 kinetochore complex component Uterus + 3.35 0.000
39 SCD stearoyl-CoA desaturase Uterus + 3.31 0.000
40 CRCT1 cysteine rich C-terminal 1 Uterus - 3.31 0.002
41 KRT13 keratin 13 Uterus - 3.30 0.010
42 CDK1 cyclin dependent kinase 1 Uterus + 3.30 0.000
43 DDIT4 DNA damage inducible transcript 4 Uterus + 3.29 0.000
44 ARMT1 acidic residue methyltransferase 1 Uterus + 3.29 0.000
45 ALOX12 arachidonate 12-lipoxygenase, 12S type Uterus - 3.28 0.000
46 ATAD2 ATPase family AAA domain containing 2 Uterus + 3.27 0.000
47 ZIC2 Zic family member 2 Uterus + 3.26 0.000
48 ARHGAP21 Rho GTPase activating protein 21 Uterus + 3.24 0.000
49 LYN LYN proto-oncogene, Src family tyrosine kinase Uterus + 3.24 0.000
50 PPIB peptidylprolyl isomerase B Uterus + 3.23 0.000
Search GEO for disease gene expression data for Cervical Cancer.
Sources

Pathways for Cervical Cancer

About this section

Pathways related to Cervical Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Proteoglycans in cancer 36
11.87 TP53 STAT3 MIR21 CCND1
2
Interleukin-4 and 13 signaling 65
11.6 TP53 STAT3 CCND1
3
MicroRNAs in cancer 36
11.59 TP53 STAT3 MIR214 MIR21 FGFR3 CCND1
4
Bladder cancer 36 1
11.36 TP53 FGFR3 CCND1
5
Hepatitis C and Hepatocellular Carcinoma 1
11.04 TP53 STAT3 CCND1
6
LncRNA-mediated mechanisms of therapeutic resistance 1
10.21 UCA1 TP53 HOTAIR
Sources

GO Terms for Cervical Cancer

About this section

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.67 TP53 MIR214 MIR21 CDKN2B-AS1
2 response to leptin GO:0044321 9.32 STAT3 CCND1
3 positive regulation of metalloendopeptidase activity GO:1904685 9.26 STAT3 MIR21
4 mitotic G1 DNA damage checkpoint GO:0031571 9.16 TP53 CCND1
5 negative regulation of superoxide dismutase activity GO:1901670 8.96 MIR21 H19
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 8.8 STAT3 MIR21 H19
Sources

Sources for Cervical Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....